McCollister-Slipp to Speak at GlobalWIN Luncheon on House Energy and Commerce Committee’s 21st Century Cures Initiative

logo  logo_globalwin_620x130_72dpiEnergyCommerceLogo_ORANGE-150x150

(Washington, DC – April 20, 2015) –  On Wednesday, April 22, Galileo Analytics Co- Founder Anna McCollister-Slipp will join Congressman Fred Upton, Chairman of the House Committee on Energy and Commerce, as well as representatives from Pfizer, Novartis and Faster Cures at a Global Women Innovation Network (GlobalWIN) luncheon, to discuss the 21st Century Cures Initiative.

Spearheaded by Chairman Upton (R-MI) and Rep. Diana DeGette (D-CO), the bi-
partisan 21st Century Cures Initiative is aimed at developing legislation that will enable and accelerate the discovery, development and delivery of new treatments, while building our nation’s capacity to continue to serve as the global hub of biomedical innovation.

Congressman Upton will provide introductory remarks, followed by a panel discussion, which includes McCollister-Slipp, along with women leaders from pharma, the Hill and patient advocacy.

More information about the luncheon is below:

Global Women’s Innovation Network Luncheon on Innovation in Healthcare in the 21st Century

 

Introductory remarks by Congressman Fred Upton. Chairman, House Committee on Energy and Commerce

Followed by a panel discussion featuring:

  • Kirsten Axelsen
    Vice President of Worldwide Policy, Pfizer, Inc.
  • Cathryn M. Clary, MD
    Head of US Medical and Chief Scientific Officer for
    US General Medicines Novartis Pharmaceuticals Corporation
  • Anna McCollister-Slipp
    Co-Founder, Galileo Analytics
  • Margaret Anderson
    Executive Director, Faster Cures
  • Carly McWilliams (moderator)
    Professional Staff, Subcommittee on Health, US House of Representatives Committee on Energy and Commerce

 

Wednesday, April 22nd, 2015
12:00pm – 1:30pm

McDermott Will & Emery
The McDermott Building
500 North Capitol Street, NW
Washington, DC

Space is Limited. RSVP to Annele Jones at Annele@HelenMilby.com

About the 21st Century Cures Initiative

In April 2014, Energy and Commerce Committee Chairman Fred Upton (R-MI) partnered with Rep. Diana DeGette (DCO) to launch the 21st Century Cures initiative. It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95 percent of [such] drugs fail during development.” Over the course of the last year, patients, providers, innovators, regulators, and researchers from around the country have provided a wide range of specific ideas on how Congress can help accelerate the discovery, development, and delivery of promising new treatments and cures for patients and maintain our nation’s standing as the biomedical innovation capital of the world. While it remains a work in progress, the legislative language included in the discussion document is based on such ideas, including proposals authored by both Republicans and Democrats.

About GlobalWIN

GlobalWIN is a 501(c)(3) organization co-chaired by Congresswoman Martha Roby and Congresswoman Debbie Wasserman Schultz that provides a dynamic forum for women executives and thought leaders in academia, government, and business who are passionate about innovation and its potential to advance critical policy issues.

###

Loading

Galileo Analytics Launches Galileo Thermometer™ to Provide Fast, Affordable and Accurate Analysis of De-Identified EHR Data from the US and Europe

(February 4, 2015 – Washington, DC)  – Galileo Analytics today announced the world-wide launch of Galileo Thermometer™, a rapid-turn around platform for providing customized analysis of de-identified electronic health record data from the US and Europe.

Galileo Thermometer™ provides pharmaceutical decision makers with access to custom-designed and developed reports, making it possible to gain a quick read or “temperature check” of specific segments of physicians and patients.

Through a partnership with Cegedim Strategic Data (CSD), Galileo Thermometer™ will draw from de-identified electronic health record data from more than 30 million patients  and greater than 30 thousand physicians in the US and the top five markets in Europe.

“For too long, pharmaceutical and biotech companies have been forced to either wait months to gain access to customized market analyses to inform their decisions,” said Simon Fitall, CEO of Galileo Analytics. “Often, they don’t have that time, so they have to make critical go, no-go decisions amidst a veritable vacuum of information, cobbling together analyst reports or outdated journal articles to inform billion dollar decisions. Galileo Thermometer is designed with these pharma decision makers in mind.”

The ease of use, flexibility and speed of Galileo Cosmos™, Galileo Analytics’ proprietary visual analytics platform, makes it possible to quickly access, view and analyze even the most complex data sets, while providing the results quickly and at an affordable price.

When combined with Cegedim Strategic Data’s extensive, longitudinal, cleansed and normalized data sets, Galileo Thermometer™ will enable all clients to get a quick read on the ‘temperature’ of the markets they need to assess to inform critical business intelligence and licensing decisions.

Galileo Thermometer™ – Fast, Accurate and Affordable

Galileo Thermometer™ will provide pharma decision makers with the option of purchasing four different levels of reports, depending on the amount of detail they need to inform their decisions. The client will have the ability to determine what data elements are most critical for them for that project, then select the level of report that fits with those needs and their budget.

Thermometer reports are designed to be affordable to small and large companies alike. The first level of report, which provides in-depth data for four distinct data elements, is available for $20,000. Prices escalate from there, depending upon the level of details, dimensions and analyses needed by the client.

About Galileo Analytics

Galileo Analytics is a visual data exploration and analytics company aimed at democratizing the ability to analyze complex health data. Galileo Analytics’ proprietary analytics platform, Galileo Cosmos™, enables any researcher, regardless of their technical skills, to conduct sophisticated, real-time analyses of clinical health data through a visually compelling, dynamic, drag-and-drop interface. For more information visit www.galileoanalytics.com.

###

Loading

Galileo Analytics’ McCollister Slipp Featured on HuffPost Live’s Davos Coverage

Screen Shot 2015-02-03 at 9.46.48 PM Screen Shot 2015-02-03 at 9.48.56 PM(Washington, DC – January 23, 2015) –  Today on HuffingtonPost Live, Galileo Analytics Co-Founder Anna McCollister-Slipp called on those attending the World Economic Forum in Davos to commit to making digital health data more available to patients, physicians and researchers.  McCollister-Slipp made her comments as part of the HuffPost Live’s coverage of the World Economic Forum’s annual gathering in Davos, Switzerland.

“I’m particularly excited that the World Economic Forum is taking on the issue of digital health at this year’s meeting, because many of the issues that are keeping us from going as far as we could with today’s technology tend to be economic decisions by corporations who have a false sense of ownership over patient data or refuse to open up data streams through APIs, so that independent developers can develop technologies that patients will use,” she said.

Echoing her comments from a column she wrote in late 2014 for the Huffington Post titled The Grim Reality of Digital Health Today, McCollister-Slipp said most investment in digital health tools are directed toward those who are focused on wellness tools or activity trackers, rather than applications aimed at helping patients manage disease, adding that those in Davos should think more strategically about how they direct their dollars to get the most from digital health investments.

“If we can get the world’s economic leaders in Davos to make this a priority, we can get really far really quickly,” she said.

McCollister-Slipp was one of three panelists interviewed by HuffPost Live anchor Nancy Redd. Other panelists included Chris Fabian, Co-Founder, UNICEF Innovation Unit and Shannon Firth, Contributor, MedPage Today.

For the full HuffPost Live segment on The Digital Health Revolution and Davos, click here.

###

Loading

Galileo Co-Founder to Discuss Roadblocks to Effective Use of Big Health Data before ONC HIT Policy Committee Workgroup

images

(Washington, DC – December 5, 2014) – Galileo Analytics co-founder Anna McCollister-Slipp will give testimony today before a meeting of the Office of the National Coordinator for Health IT’s Policy Committee’s Privacy and Security Workgroup.

McCollister-Slipp will join a roster of experts on various aspects of big health data. the agenda covers topics ranging from the potential benefits and opportunities of health data to create a learning health system to methods for ensuring patient privacy and security.  McCollister-Slipp will address the workgroup at 2:30 pm EST, providing a patient perspective on concerns about the use of big data in health care.

  • Other speakers during the day include:
  • Rich Platt, Harvard Pilgrim healthcare Institute
  • Steve Downs, Robert Wood Johnson Foundation
  • Patti Brennan, University of Wisconsin-Madison College of Engineering
  • Michele DeMooy, Center for Democracy and Technology
  • Mark Savage, Ntional Partnership for Women and Families
  • Khaled El Emam, University of Ottawa
  • Bob Gellman, private consultant
  • Fred Cate, Indiana University Maurer School of Law
  • Deven McGraw, Chair, Manatt, Phelps & Phillips, LLP
  • Stanley Crosley, Co-Chair, Drinker Biddle & Reath LLP

For more information about today’s meeting and to join the meeting virtually, visit:

http://www.healthit.gov/facas/calendar/2014/12/05/policy-privacy-security-workgroup-virtual-hearing

###

Loading

McCollister-Slipp to Clinical Researchers: Find Ways to Incorporate Patient-Generated Health Data into Clinical Trials

(New York, NY – November 17, 2014) – Galileo Analytics Co-Founder Anna McCollister-Slipp today called on pharmaceutical companies and the Food and Drug Administration to find ways to incorporate new forms of patient-generated health data into clinical trials. McCollister-Slipp made her remarks as part of a panel on patient-generated health data at this year’s Partnering for Cures conference in New York, sponsored by Faster Cures and the Milken Institute.

McCollister-Slipp was among a select group of genomics experts, researchers and technology developers discussing the promise of new digital health and genomic data Screen Shot 2015-02-03 at 8.22.39 PM Screen Shot 2015-02-03 at 8.16.33 PMsources for transforming clinical research, as well as the barriers to including new, innovative patient-generated data streams into clinical research. Panel members included:

  • Eric Green, Director, National Human Genome Research Institute, National Institutes of Health
  • Anna McCollister-Slipp, Co-Founder, Galileo Analytics
  • Tom Parsons, Co-Founder, HealthXL
  • Eric Schadt, Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine, Mount Sinai
  • Ravi Seshadri, Vice President, Technology, NantHealth
  • Todd Sherer, CEO, The Michael J. Fox Foundation for Parkinson’s Research (moderator)

McCollister-Slipp appealed to Pharmaceutical and medical device researches to bring patients into the process of designing research protocols, which she says might help increase the patient participation in clinical research.

Referencing a clinical trial for a new diabetes drug in which she participated in 2013, she said “Everything about the trial process was designed for the convenience of everybody in the study process but the patients. Despite the fact that one of the big buzzwords in recent years is patient-centeredness, It was painfully obvious that the protocol designers had never consulted anybody who had lived with the disease.”

For a full video and more coverage of the panel click here.

###

Loading

McCollister-Slipp to Informaticists: Make data liquid!

(Washington, DC – November 16, 2014) – Galileo Analytics Co-Founder Anna McCollister-Slipp today called on medical informaticists to prioritize “data liquidity” and the free flow of health data and to do so with a sense of urgency that the issue deserves. Her remarks were made during a panel discussion on the opening day of this year’s American Medical Informatics Association (AMIA) meeting in Washington, DC.

“Until we get to the point where data is flowing freely among health care providers, medical devices and patients we will make little progress in improving patient care with health information technology,” she said. “Interoperability and ‘data liquidity’ are essential if we ever hope to see innovation that enables individuals to better manage their own health and physicians to better care for their patients.”

“We’ve invested $33 billion in taxpayer money and billions more in private investment to essentially replicate in digital form the acute care and specialty care system that has failed to meet our needs for decades,” she said. “We’ve made tremendous progress in many ways, but little else will change unless we can find a way to get data out of the silos and flowing freely.”

McCollister-Slipp was one of four panelists speaking about emerging platforms for patient-centered care. The panel was part of the AMIA Workshop on Interactive Systems in Healthcare. More information about the conference and panel are below:

Emerging Platforms for Person-Centered, Community-Wide Care Coordination: Needs, Challenges, and Solutions

Katherine K. Kim, PhD, MPH, MBA, University of California Davis (chair and moderator)

Charles Boicey, MS, RN-BC, CPHIMS, State University of New York Stony Brook

Janet Freeman-Daily, Seattle, WA

Susan Hull, MSN, RN, Wellspring Consulting

Anna McCollister-Slipp, Galileo Analytics

Abstract

As the population ages and the burden of disease increases, there is great need for community-wide care coordination (CWCC) to help deliver triple aims of improved quality, population health and cost. This is particularly critical for underserved patients such as those in rural and low-income communities who experience health disparities. The complexity of coordinating across multiple institutions, care teams, and community services while maintaining a sharp focus on person-centeredness necessitates robust and adaptive technologies. Such systems are foundational for accountable care organizations and health home models. There is little known about technology platforms to accomplish this goal. An initial review of 20 commercially available systems marketed as fulfilling care coordination and patient engagement were assessed on 24 criteria. Most systems were lacking features for patient engagement and collaboration across multiple organizations. A diverse panel of patients, researchers, clinicians, and designers will consider and debate the needs and challenges of person-centered CWCC as well as promising technology solutions.

About AMIA

AMIA, the leading professional association for informatics professionals, is the center of action for 4,000 informatics professionals from more than 65 countries. As the voice of the nation’s top biomedical and health informatics professionals, AMIA and its members play a leading role in assessing the effect of health innovations on health policy, and advancing the field of informatics. AMIA actively supports five domains in informatics: translational bioinformatics, clinical research informatics, clinical informatics, consumer health informatics, and public health informatics.

 

###

Loading

Galileo Analytics Co-Founder Appointed to Stakeholder Panel of ACC’s Diabetes Collaborative Registry

diabetes-logo

(Washington, DC – October 7, 2014) – The American College of Cardiology has appointed Galileo Analytics Co-Founder Anna McCollister-Slipp to serve on the Stakeholder Advisory Panel of its newly created Diabetes Collaborative Registry.

The Diabetes Collaborative Registry™ is the first global, cross-specialty, clinical diabetes registry designed to track and improve the quality of diabetes and metabolic care across the primary care and specialty care continuum.

The American College of Cardiology (ACC) and AstraZeneca, in partnership with the American Diabetes Association, American College of Physicians, and the Joslin Diabetes Center have joined forces to integrate compelling, data-rich assets to provide a unique, longitudinal view into the patient journey for those with diabetes and, ultimately, one day be able to transform the future of diabetes care.

The unique, real-world collaboration among multi-disciplinary providers is designed to help transform the future of diabetes treatment and prevention and improve the lives of billions.

The Stakeholder Advisory Panel panel includes representatives from physician organizations, academic researchers, advocacy groups, data analytics experts and diabetes patients. Panel members include:

William J. Oetgen, M.D., M.B.A., F.A.C.C., American College of Cardiology

Jane L. Chiang, M.D. , American Diabetes Association

Laura Lee Hall, Ph.D. , American College of Physicians

Catherine Carver, M.S., A.N.P., C.D.E., Joslin Diabetes Center

Anna McCollister-Slipp, Galileo Analytics

Gregory A. Nichols, Ph.D., M.B.A., F.A.H.A., Kaiser Permanente Center for Health Research

John W. Kennedy, M.D., Geisinger Health System

David C. Klonoff, M.D., F.A.C.P., F.R.C.P (Edin), Fellow AIMBE, Mills-Peninsula Health Services, Journal of Diabetes Science & Technology

Gary Puckrein, Ph.D., National Minority Quality Forum

Brian Anderson, M.D., athenaHealth

Jennifer Covich Bordenick, eHealth Initiative

Sandra Leonard, M.P.H., AstraZeneca

Javier Jimenez, M.D., M.P.H., AstraZeneca

William S. Cook, Ph.D., AstraZeneca

Iftekhar Kalsekhar, Ph.D., AstraZeneca

Mikhail Kosiborod, M.D., F.A.C.C., F.A.H.A., Saint Luke’s Mid America Heart Institute

Silvio Inzucchi, M.D., Yale Diabetes Center

Jennifer L. Wong, M.P.P., American College of Cardiology

More information about the Diabetes Collaborative Registry can be found at http://www.ncdr.com.

###

Loading

Galileo Analytics Co-Founder Featured in US News’ Annual Hospital Rankings Issue

85

(Washington, DC – August 4, 2014) –  The 2014 edition of US News and World Report’s annual “Best Hospitals” issue hit the stands today, featuring Galileo Analytics Co-Founder Anna McCollister-Slipp in an article about the future of digital health.

Written by veteran journalist Elizabeth Gardner, the article discusses McCollister-Slipp’s use of digital health and wellness tools to manage her type 1 diabetes and the promise of these digital technologies to transform healthcare, as well as her frustration with a lack of data access and medical device interoperability and how that unnecessarily inhibits the devices’ value for patients.

In addition to McCollister-Slipp, the article features noted digital health experts, such as Dr. Eric Topol of the Scripps Translational Science Institute, Dr. Danny Sands of the Beth Israel Deaconess Medical Center and Co-Founder of the Society for Participatory Medicine and Dr. Farzad Mostashari, former National Coordinator of the Office of Information Technology at the Department of Health and Human Services.

To read the full article visit www.health.usnews.com or click here: “Need a Diagnosis or Checkup? Your Smartphone Is On Call: Apps and handheld devices are revolutionizing care

###

Loading